AzTrials
AzTrials

HealthyNCT01778231

Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation

A study testing Nutrof Total in people with Healthy, run by Queen's University, Belfast at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to investigate genetic and environmental determinants of macular pigment (MP) and assess the effects of lutein and zeaxanthin-rich supplements on macular pigment levels. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Nutrof Total
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
56 participants
Where
1 siteUnited Kingdom
Study dates
Mar 2011to Dec 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • healthy volunteers,
  • male or female,
  • aged 18-50 years

Who cannot join

  • evidence of eye disease,
  • inability to give informed written consent,
  • any other health problem which would interfere with ability to adhere to the study protocol.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Centre for Public Health

    Belfast, Antrim, BT126BA

Other trials in United Kingdom

About this study

This study aims to investigate genetic and environmental determinants of macular pigment (MP) and assess the effects of lutein and zeaxanthin-rich supplements on macular pigment levels.

Read the detailed description

Age-related macular degeneration is the leading cause of blindness in elderly people in western countries1. It is a degenerative condition of the macula characterized by the death or dysfunction of photoreceptors, leading to the progressive loss of central vision1. Central vision is needed for activities requiring fine vision such as reading, driving or recognizing faces. With the aging population and increasing expectations in health care it is therefore of utmost importance to preserve the quality of life and independence of the elderly through prevention of this ocular disease.

Much interest surrounds macular pigment due to its putative role in protecting the macula from oxidative stress and age-related degenerative change2, yet much is still unknown about factors that determine its uptake and deposition. Large inter-individual differences in MP have been demonstrated with several large population based studies showing that peak macular pigment density can vary by over a factor of 10 between individuals3-4. Subsequent studies have suggested a number of parameters such as age, diet, percentage body fat, gender and tobacco use5-9 as determinants of MP, however these only account for approximately a third of the variance leaving a significant proportion unexplained.

Lutein and Zeaxanthin (L and Z), constituents of MP, cannot be synthesized by the body and so are entirely dietary in origin. They are present in foods such as collard greens, spinach and Brussels sprouts10. Variation in the bitter-taste receptor gene, TAS2R38 confers the ability to taste 6-n-propylthiouracil (PROP) and phenylthiocarbamide (PTC) which is present in many of these foods11. People who taste PTC with a greater intensity are more likely to avoid these foods and therefore we hypothesize they may have lower levels of macular pigment. Thus, this study may help to identify a group at higher risk of macular degeneration.

Despite MP's dietary origin only modest correlations exist with serum and dietary levels of L and Z, and although the level of MP can be augmented in most people by diet or supplementation the response is variable and not always correlated with baseline level. Most supplementation studies identify a sub-group of "retinal non-responders"12 in which serum values of the carotenoids have risen, yet no change is found in macular pigment, the reason for this is not clear. The first part of our study will provide a well-phenotyped group in which to explore this further. Several studies have also shown that peak macular pigment levels are strongly heritable13-14 suggesting genetics may play an important role. Although no gene has currently been clearly identified the ApoE gene has been suggested to show an association with macular pigment level. A supplementation study in this population will be able to determine whether the genes identified on a cross-sectional basis do determine uptake of the nutritional supplement. We may also be able to identify specific demographic or lifestyle factors of non-responders which may help to explain the phenomenon.

  1. Carpentier S, Knaus M, Suh M. Associations between Lutein, Zeaxanthin, and Age-Related Macular Degeneration: An Overview. Clinical Reviews in Food Science and Nutrition. 2009 49:313-326
  2. Whitehead AJ, Mares J, Danis RP. Macular Pigment: A Review of Current Knowledge. Arch Opthamol. July 2006; 124: 1038-1045
  3. Ciulla TA, Curran-Celantano J, Cooper DA, et al. Macular pigment optical density in a midwestern sample. Ophthalmology. Apr 2001;108(4):730-737.
  4. Hammond BR, Jr., Caruso-Avery M. Macular pigment optical density in a Southwestern sample. Invest Ophthalmol Vis Sci. May 2000;41(6):1492-1497.
  5. Hammond BR, Jr., Curran-Celentano J, Judd S, et al. Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns. Vision Res. Jul 1996;36(13):2001-2012.
  6. Hammond BR, Jr., Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Res. Sep 1996;36(18):3003-3009.
  7. Ciulla TA, Hammond BR, Jr. Macular pigment density and aging, assessed in the normal elderly and those with cataracts and age-related macular degeneration. Am J Ophthalmol. Oct 2004;138(4):582-587.
  8. Curran-Celentano J, Hammond BR, Jr., Ciulla TA, Cooper DA, Pratt LM, Danis RB. Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr. Dec 2001;74(6):796-802.
  9. Nolan J, O'Donovan O, Kavanagh H, et al. Macular pigment and percentage of body fat. Invest Ophthalmol Vis Sci. Nov 2004;45(11):3940-3950.
  10. Carpentier S, Knaus M, Suh M. Associations between Lutein, Zeaxanthin, and Age-Related Macular Degeneration: An Overview. Critical Reviews in Food Science and Nutrition. 2009; 49(4): 313-326
  11. Bachmanov A, Beauchamp G. Taste Receptor Genes. Annual Review of Nutrition. 2007.27:389-414
  12. Hammond BR, Jr., Johnson EJ, Russell RM, et al. Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci. Aug 1997;38(9):1795-1801.
Conditions
Healthy
Being tested
Nutrof Total, Placebo
Keywords
Focus, uptake, Lutein, Zeaxanthin, individuals

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nutrof TotalDietary supplement

    Antioxidant and trace element supplement

  • PlaceboDietary supplement

Study groups in NCT01778231
Study groupRoleWhat they receive
Vitamin SupplementExperimental1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
Receives: Dietary Supplement: Nutrof Total
Inert oil capsulePlacebo comparator1 capsule daily for 16 weeks
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Macular Pigment Measurement

    Macular Pigment Measurement using Heterochromatic Flicker Photometry

    Measured: 16 weeks

Secondary outcomes (2)
  1. Serum Lutein and Zeaxanthin

    Measured: 16 weeks

  2. Macular Pigment (reflectometry)

    Macular Pigment level measured using reflectometry

    Measured: 16 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2013 (estimated)
  2. Study startMar 2011
  3. Primary completionMay 2013
  4. Study completionDec 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
56 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01778231
Sponsor's protocol ID
11/05v1
Status last verified
Aug 2019
First submitted
25 Jan 2013
Last updated
14 Aug 2019
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Nutrof Total in people with Healthy, run by Queen's University, Belfast at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Macular Pigment Measurement (time frame: 16 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in